>>Signaling Pathways>>(R,S)-N-Nitrosoanatabine

(R,S)-N-Nitrosoanatabine (Synonyms: N-NAT, N’-Nitrosoanatabine)

Catalog No.GC48939

A tobacco-specific nitrosamine

Products are for research use only. Not for human use. We do not sell to patients.

(R,S)-N-Nitrosoanatabine Chemical Structure

Cas No.: 887407-16-1

Size 가격 재고 수량
1mg
US$170.00
재고 있음
5mg
US$425.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(R,S)-N-Nitrosoanatabine (N-NAT) is a tobacco-specific nitrosamine (TSNA) that has been found in tobacco, tobacco products, and electronic cigarettes.1,2 The (S) enantiomer comprises approximately 80% of the N-NAT found in commercial and research cigarettes and smokeless tobacco.3 Unlike other TSNAs, N-NAT is not carcinogenic in rats when administered at doses of 1, 3, and 9 mmol/kg.1

1.Hoffmann, D., Rivenson, A., Amin, S., et al.Dose-response study of the carcinogenicity of tobacco-specific N-nitrosamines in F344 ratsJ. Cancer Res. Clin. Oncol.108(1)81-86(1984) 2.Kim, H.-J., and Shin, H.-S.Determination of tobacco-specific nitrosamines in replacement liquids of electronic cigarettes by liquid chromatography-tandem mass spectrometryJ. Chromatogr. A129148-55(2013) 3.Carmella, S.G., McIntee, E.J., Chen, M., et al.Enantiomeric composition of N'-nitrosonornicotine and N'-nitrosoanatabine in tobaccoCarcinogenesis21(4)839-843(2000)

리뷰

Review for (R,S)-N-Nitrosoanatabine

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (R,S)-N-Nitrosoanatabine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.